Table 3 Summary of treatment-related adverse events with second-line IBI318 plus lenvatinib
Event | Total (N = 40) | |
|---|---|---|
Any grade | Grade ≥3 | |
Any treatment-related adverse events, n (%) | 33 (82.5) | 5 (12.5) |
Adverse event leading to temporary interruption of study drugs, n (%) | 10 (25.0) | 3 (7.5) |
Hematological toxicities | ||
Decreased white blood cell count, n (%) | 3 (7.5) | 0 (0.0) |
Decreased neutrophil count, n (%) | 4 (10.0) | 0 (0.0) |
Decreased platelet count, n (%) | 1 (2.5) | 0 (0.0) |
Anemia, n (%) | 3 (7.5) | 0 (0.0) |
Non-hematological toxicities | ||
Alanine aminotransferase increased, n (%) | 7 (17.5) | 1 (2.5) |
Aspartate aminotransferase increased, n (%) | 5 (12.5) | 1 (2.5) |
Blood bilirubin increased, n (%) | 8 (20.0) | 0 (0.0) |
Weight decreased, n (%) | 2 (5.0) | 0 (0.0) |
Blood thyroid-stimulating hormone increased, n (%) | 11 (27.5) | 0 (0.0) |
Blood thyroid-stimulating hormone decreased, n (%) | 4 (10.0) | 0 (0.0) |
Headache, n (%) | 2 (5.0) | 1 (2.5) |
Blood pressure increased, n (%) | 2 (5.0) | 0 (0.0) |
Infusion-related reaction, n (%) | 8 (20.0) | 1 (2.5) |
Diarrhea, n (%) | 3 (7.5) | 0 (0.0) |
Constipation, n (%) | 2 (5.0) | 0 (0.0) |
Nausea, n (%) | 1 (2.5) | 0 (0.0) |
Vomiting, n (%) | 3 (7.5) | 0 (0.0) |
Toothache, n (%) | 1 (2.5) | 0 (0.0) |
Abdominal distension, n (%) | 1 (2.5) | 0 (0.0) |
Hemoptysis, n (%) | 4 (10.0) | 0 (0.0) |
Productive cough, n (%) | 3 (7.5) | 0 (0.0) |
Cough, n (%) | 4 (10.0) | 0 (0.0) |
Rash, n (%) | 5 (12.5) | 1 (2.5) |
Pruritus, n (%) | 1 (2.5) | 0 (0.0) |
Fatigue, n (%) | 8 (20.0) | 0 (0.0) |
Chest discomfort, n (%) | 1 (2.5) | 0 (0.0) |
Proteinuria, n (%) | 1 (2.5) | 0 (0.0) |
